ACS Biomarker is a biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers for cardiovascular disease, in particular heart failure. There is a high need for novel markers to improve cardiovascular risk assessment. ACS Biomarker currently develops a multi-marker test that can improve the clinical management of heart failure. In our recently opened new lab, a series of miRNAs is measured in thousands of patient samples in a high-throughput setting. Accuracy, reproducibility, and time management are key elements in this process. We therefore automated the pre-PCR step; a high-risk factor in validating miRNAs.
Joost Leenders, ACS Biomarker